Holen Sie sich die Stockscreener-App
93.61
0.06%
0.06
Handel nachbörslich:
93.61
Schlusskurs vom Vortag:
$93.55
Offen:
$93.23
24-Stunden-Volumen:
9.61M
Relative Volume:
0.99
Marktkapitalisierung:
$138.83B
Einnahmen:
$19.35B
Nettoeinkommen (Verlust:
$2.78B
KGV:
50.07
EPS:
1.8696
Netto-Cashflow:
$3.82B
1W Leistung:
+2.64%
1M Leistung:
-2.55%
6M Leistung:
-11.81%
1J Leistung:
-8.47%
1-Tages-Spanne:
$92.70
$93.92
1-Wochen-Bereich:
$90.44
$94.75
52-Wochen-Spanne:
$85.98
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Vergleichen Sie BSX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-03 | Herabstufung | Erste Group | Buy → Hold |
| 2025-09-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-16 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-16 | Hochstufung | Needham | Hold → Buy |
| 2025-01-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Herabstufung | Needham | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
Boston Scientific completes Nalu Medical acquisition - MassDevice
Transcatheter Embolization and Occlusion Devices Market Size to be Valued at USD 11.53 Billion by 2033, Driven by Rising Oncology and Neurovascular Interventions – SNS Insider - GlobeNewswire Inc.
Boston Scientific (BSX) stock ticks higher again — what to watch before Tuesday’s trade - TechStock²
Boston Scientific to acquire Alameda-based Penumbra for $14.5 billion - MSN
Boston Scientific (BSX) Sees Surge in Call Options Activity - GuruFocus
Boston Scientific stock rises as Evercore taps BSX for a tactical list ahead of earnings - TechStock²
Lbp Am Sa Increases Position in Boston Scientific Corporation $BSX - MarketBeat
Evercore ISI reiterates Outperform rating on Boston Scientific stock - Investing.com
Hospitals are embracing pulsed field ablation. Here’s why - Modern Healthcare News
Algebris UK Ltd. Invests $1.77 Million in Boston Scientific Corporation $BSX - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Has $72.29 Million Stake in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific stock navigates a cautious upswing as Wall Street leans bullish - AD HOC NEWS
UniSuper Management Pty Ltd Boosts Holdings in Boston Scientific Corporation $BSX - MarketBeat
What Does the Market Think About Boston Scientific Corp? - Sahm
Oppenheimer Questions Valuation of Boston Scientific's $14.5 Billion Penumbra Deal - Finviz
Oppenheimer Questions Valuation of Boston Scientific’s $14.5 Billion Penumbra Deal - Yahoo Finance
Boston Scientific stock price: BSX ends higher as Fitch turns credit outlook positive ahead of key catalysts - TechStock²
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Boston Scientific ratings affirmed by Fitch, outlook positive - Investing.com
Boston Scientific stock (BSX) climbs as heart-rhythm rivalry and deal risk stay in play - TechStock²
Teacher Retirement System of Texas Has $77.67 Million Stake in Boston Scientific Corporation $BSX - MarketBeat
iA Global Asset Management Inc. Acquires 31,717 Shares of Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corporation (NYSE:BSX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Oppenheimer Questions $14.5B Penumbra Deal Valuation Despite Boston Scientific's (BSX) Mew Market Dominance - Finviz
A Closer Look at Boston Scientific's Options Market Dynamics - Benzinga
Boston Scientific announces agreement to acquire Penumbra, Inc. - Quantisnow
Boston Scientific Corporation (NYSE:BSX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Boston Sci secures CE mark for Embold system - BioWorld MedTech
Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface - Benzinga
Boston Scientific (BSX) to acquire Penumbra in $14.5B neurovascular push - Stock Titan
Universal Beteiligungs und Servicegesellschaft mbH Reduces Holdings in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific (BSX): Company Profile, Stock Price, News, Rankings - Fortune
Boston Scientific to acquire Penumbra (NYSE: PEN) in $14.5B deal - Stock Titan
Investors Purchase Large Volume of Call Options on Boston Scientific (NYSE:BSX) - MarketBeat
Boston Scientific stock rises as BSX teases new pain-therapy data while FDA stent alert hangs over shares - TechStock²
Boston Scientific has a potentially serious Axios stent recall - MassDevice
Boston Scientific stock rating reiterated at Outperform by Mizuho - Investing.com
Boston Scientific recalls stent over issue linked to 3 deaths - MedTech Dive
3 takeaways from Boston Scientific’s $14.5B Penumbra deal - MedTech Dive
Boston Scientific to Acquire Alameda-Based Penumbra for $14.5 Billion - alamedapost.com
Analysts Are Bullish on These Healthcare Stocks: Henry Schein (HSIC), Boston Scientific (BSX) - The Globe and Mail
Canaccord Genuity downgrades Penumbra stock to Hold after Boston Scientific deal - Investing.com
Penumbra shares soar pre-market — what is the Boston Scientific agreement? - MSN
Boston Scientific to Acquire Penumbra - Diagnostic and Interventional Cardiology
Boston Scientific’s Strategic Acquisition Tests Investor Resolve - AD HOC NEWS
Allstate Corp Has $5.31 Million Stake in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific to acquire Penumbra, expanding cardiovascular portfolio - Today's Medical Developments
Penumbra Shares Soar Pre-MarketWhat Is The Boston Scientific Agreement? - Menafn
UnitedHealth Stock Slips Amid Medicare Investigation; Boston Scientific to Acquire Penumbra for $14.5B - Intellectia AI
Is Boston Scientific Corporation (NYSE:BSX) Worth US$88.1 Based On Its Intrinsic Value? - Yahoo Finance
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.68%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):